A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies
Completed
Millennium Pharmaceuticals, Inc.
Phase 1
The purpose of this study was to evaluate the safety and to determine dose-limiting
toxicities (DLTs), maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), and
dosing schedules of oral TAK-228+TAK-117. It also evaluated the single- and multiple-dose
plasma pharmacokinetics (PK) of TAK-228+TAK-117 in participants with advanced nonhematologic
malignancies.
Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer
Completed
Millennium Pharmaceuticals, Inc.
Phase 2
This is a phase 1b/2 study of the safety and efficacy of sapanisertib (MLN0128) in
combination with exemestane or fulvestrant therapy in women with estrogen receptor
positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) advanced or metastatic
breast cancer who progressed on treatment with everolimus in combination with exemestane or
fulvestrant.
Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma
Active, not recruiting
National Cancer Institute (NCI)
Phase 1
This partially randomized pilot phase I trial studies how much sapanisertib reaches the brain
tumor and how well it works when given before and after surgery in treating patients with
glioblastoma that has grown or come back and requires surgery. Sapanisertib may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.